Harbour BioMed Presents Novel Antibody for Cancer Immunotherapy at 2021 American Association for Cancer Research Annual Meeting

CAMBRIDGE,Mass.,SUZHOU,China andROTTERDAM,Netherlands,April 13,2021 -- Harbour BioMed ("HBM"; HKEX: 02142.HK),a global clinical-stage biopharmaceutical company,presents its newly discovered fully human anti-B7H7 monoclonal antibody at the American Association for Cancer Research Annual Meeting. This meeting is being held virtually from April 10-15,2021. The anti-B7H7 antibody is a novel immune-oncology antibody with potent anti-tumor activity generated using HBM's proprietary H2L2 Harbour Mice® platform.

Details of the presentation:

Harbour BioMed's presentation

By leveraging its innovative discovery engine based on the Harbour Mice® antibody platforms,HBM has built a sustained capability to deliver novel antibody therapeutics in the field of oncology and immunology. Following the previously reported monoclonal antibody against a novel target CCR8,HBM now reports another first-in-class therapeutic antibody targeting a novel immune checkpoint - B7H7. B7H7 is mainly expressed in some PD-L1 negative/low tumors and may serve as an alternative immune escape pathway for these tumors. This antibody generated from H2L2 Harbour Mice® demonstrates excellent preclinical activity and anti-tumor efficacy.

About B7H7

B7H7 is a novel immune checkpoint of B7 family,which is highly expressed on a variety of human cancers including colon,pancreatic,kidney,breast,bladder,lung cancers,etc. and is associated with metastatic disease and poorer survival rate of these patients. B7H7 antibody may present a novel anti-tumor therapy complementary to PD-L1/PD1 based therapy. B7H7 antibodies show significant T cell activation effect in vitro and tumor growth inhibition in several mouse tumor models.

About Harbour BioMed

Harbour BioMed (HKEX: 02142.HK) is a global biopharmaceutical company committed to the discovery,development and commercialization of novel antibody therapeutics focusing on oncology and immunology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability,collaborations with co-discovery and co-development partners and select acquisitions.

The Company's proprietary antibody technology platforms Harbour Mice® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format,as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies,the HCAb-based immune cell engagers (HBICETM) are capable of delivering tumor killing effects unachievable by traditional combination therapies. Integrating Harbour Mice®with single B cell cloning platform,our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies.

For more information,please visitwww.harbourbiomed.com

View original content to download multimedia:/news-releases/harbour-biomed-presents-novel-antibody-for-cancer-immunotherapy-at-2021-american-association-for-cancer-research-annual-meeting-301267322.html